

AMOXIGRAN GRANULES

VIAMOxx-0 (MY)_3

DESCRIPTION

White to pale yellow granules with grenadine flavour. White to yellowish suspension upon reconstitution.

COMPOSITION

Amoxicillin Trihydrate equivalent to amoxicillin 125 mg/5 ml after reconstitution.

Amoxicillin Trihydrate equivalent to amoxicillin 250 mg/5 ml after reconstitution.

PHARMACODYNAMICS

Amoxicillin is a semi synthetic penicillin which is acid resistant and bactericidal and has a similar antibacterial spectrum to ampicillin.

It has been reported that amoxicillin predominantly inhibits side-wall synthesis in susceptible bacteria while ampicillin mainly inhibits cross-wall synthesis, probably by acylation of membrane-bound transpeptidase enzymes. This prevents cross-linkage of peptidoglycan chains which is necessary for bacteria frequently occurs.

Amoxicillin has been reported to be slightly more active than ampicillin against some streptococci and salmonella spp. But less active against shigella spp. It is inactivated by penicillinase and complete cross-resistance has been reported between amoxicillin and ampicillin.

PHARMACOKINETICS

Absorption: Amoxicillin is stable to gastric acid and 50 to 90% of a dose is absorbed after oral administration; absorption is more complete than that of ampicillin and it is not greatly influenced by the presence of food.

Blood Concentration: After an oral dose of 500mg, peak serum concentrations of 3 to 20µ/ml are attained in 1 to 2 hours; detectable concentrations are present after 8 hours; peak concentrations occur earlier in children and infants by later in neonates. It is reported to produce peak plasma concentrations that are up to twice as high as those from the same dose of ampicillin.

Half-life: Serum half life, 1 hour which may be increased to 15 hours in renal failure.

Distribution: Enters most tissues and fluids but is not detectable in the cerebrospinal fluid even when the meninges are inflamed; crosses the placenta and small amounts are secreted in the milk; volume of distribution at steady-state serum concentrations, about 0.3 litres/kilogram body-weight.

It also penetrates well into purulent and mucoid sputum and low concentrations have low concentrations have been found in ocular fluid.

Protein binding: 15-25% bound to plasma proteins.

Metabolic reactions: Metabolised to inactive metabolites in the liver and to 10 to 25% appears to be converted to penicilloic acid.

Excretion: About 60% of an oral dose is excreted unchanged in the urine in 6 hours by glomerular filtration and tubular secretion. Urinary excretion is delayed by probenecid and it also occurs more slowly in the newborn; small amounts are excreted in the bile.

INDICATIONS

For treatment of:

- Ear, nose and throat infections caused by *streptococci*, *pneumococci*, *nonpenicillinase* - producing staphylococci and *H. influenzae*.
- Genitourinary tract infections caused by *E. coli*, *P. mirabilis*, *S. faecalis*.
- Skin and soft tissues infections caused by streptococci, nonpenicillinase - producing staphylococci and *E. coli*.
- Urogenital and urethral gonorrhoea caused by *N. gonorrhoeae*.

CONTRAINDICATIONS

- Contraindicated in patients known to be sensitive to penicillin.
- Avoid in patients with infectious mononucleosis because of increased risk of skin rashes.

PRECAUTIONS

- During prolonged therapy, periodic assessment of renal, hepatic and haematopoietic function should be made as with any potent drug.

- The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving *Enterobacter*, *Pseudomonas* or *Candida*), the drug should be discontinued and/or appropriate therapy instituted.
- Safety for use in pregnancy has not been established.

WARNING

Serious and occasionally fatal hypersensitivity (anaphylactoid and severe cutaneous adverse reactions) reactions have been reported in patients on penicillin therapy although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before therapy with any penicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens. If an allergic reaction occurs, appropriate therapy should be instituted and discontinuance of amoxicillin therapy considered. Serious anaphylactoid reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated.

Not to be used in patients with known hypersensitivity to Penicillin.

SIDE/ADVERSE EFFECTS

- **Skin and subcutaneous tissue disorders:** Frequency 'very rare': Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- **Hypersensitivity reactions:** Rash (urticarial, erythematous, morbilliform) and less frequently, as exfoliative dermatitis or erythema multiforme.
- **Haemolytic effects:** Haemolytic anaemia, anaemia, eosinophilia, leukopenia, neutropenia, agranulocytosis, thrombocytopenia, thrombocytopenic purpura.
- **G.I. effects:** Diarrhoea, nausea, vomiting, black hairy tongue, glossitis, stomatitis, sore mouth or tongue.
- **Renal effect:** Acute interstitial nephritis.
- **Hepatic effects:** A moderate increase in serum concentration of AST (SGOT).

DRUG INTERACTIONS

- Concurrent use with allopurinol or probenecid requires careful monitoring.
- Concurrent use with chloramphenicol, erythromycins, sulphonamides and tetracycline may interfere with the bactericidal effect of amoxicillin.

OVERDOSAGE

Clinical features: Anorexia, nausea, vomiting, abdominal discomfort, diarrhoea.

Treatment for overdosage: Emesis or gastric lavage if appropriate. Symptomatic and supportive measures.

DOSAGE AND ADMINISTRATION

Adult:

Oral, 250 to 500 mg every eight hours; or as directed.

Children:

- Infants up to 6 kg of body weight:
Oral, 25 - 50 mg every 8 hours.
- Infants 6 - 8 kg of body weight:
Oral, 50 - 100 mg every 8 hours.
- Infants and children 8 - 20 kg of body weight:
Oral, 6.7 - 13.3 mg/kg of body weight.
- Children 20 kg of body weight and over:
See adult dose.

The information given here is limited. For further information, consult your doctor or pharmacist.

Storage:

Store below 30°C. Protect from moisture. After reconstitution: Use within 10 days. Refrigerate after reconstitution at 2°C - 8°C.

Presentation/Packing:

Granules 60 ml and 100 ml after reconstitution.

Product Registration Holder /
Manufactured by: HOVID Bhd.
121, Jalan Tunku Abdul Rahman
(Jalan Kuala Kangsar),
30010 Ipoh, Perak, Malaysia.

Revision date: November 2020

